Search research articles
Contact Us
Filters
Showing results (11-20 of 48) with videos related to
Page
of 5
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 20, 2012
18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma
Benjamin Kasenda, Vanessa Haug, Elisabeth Schorb, et al.
Journal of Neurology
|
March 8, 2018
The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis
Tilman Hottenrott, Elisabeth Schorb, Kristina Fritsch, et al.
Annals of Hematology
|
July 13, 2014
Chronic hepatitis E virus infection following allogeneic hematopoietic stem cell transplantation: an important differential diagnosis for graft versus host disease
Dominik Bettinger, Elisabeth Schorb, Daniela Huzly, et al.
Haematologica
|
January 23, 2025
Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma
Julia Wendler, Richard I Lewis, Alexandra Kutilina, et al.
European Journal of Pediatrics
|
March 28, 2007
Early atherosclerosis in childhood type 1 diabetes: role of raised systolic blood pressure in the absence of dyslipidaemia
Karl Otfried Schwab, Jürgen Doerfer, Andreas Krebs, et al.
Hematological Oncology
|
June 29, 2023
Central nervous system lymphomas-Assessment and treatment and prevention of central nervous system relapse
Paola Ghione, Katharine L Lewis, Sabela Bobillo, et al.
Cancers
|
February 13, 2026
The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System
Julia Wendler, Benjamin Kasenda, Eliza M Lauer, et al.
BMC Cancer
|
April 22, 2016
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix)
Elisabeth Schorb, Juergen Finke, Andrés J M Ferreri, et al.
BMC Cancer
|
September 10, 2022
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma
Julia Wendler, Christopher P Fox, Elke Valk, et al.
Cancers
|
December 11, 2025
Role of Geriatric Assessment Scores as Predictors of Intensive Therapy Feasibility and Survival in Elderly Patients with Primary CNS Lymphoma
Lisa K Isbell, Annika Vreden, Gabriele Ihorst, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 48) with videos related to
Sort By:
Page
of 5
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 20, 2012
18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma
Benjamin Kasenda, Vanessa Haug, Elisabeth Schorb, et al.
Journal of Neurology
|
March 8, 2018
The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis
Tilman Hottenrott, Elisabeth Schorb, Kristina Fritsch, et al.
Annals of Hematology
|
July 13, 2014
Chronic hepatitis E virus infection following allogeneic hematopoietic stem cell transplantation: an important differential diagnosis for graft versus host disease
Dominik Bettinger, Elisabeth Schorb, Daniela Huzly, et al.
Haematologica
|
January 23, 2025
Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma
Julia Wendler, Richard I Lewis, Alexandra Kutilina, et al.
European Journal of Pediatrics
|
March 28, 2007
Early atherosclerosis in childhood type 1 diabetes: role of raised systolic blood pressure in the absence of dyslipidaemia
Karl Otfried Schwab, Jürgen Doerfer, Andreas Krebs, et al.
Hematological Oncology
|
June 29, 2023
Central nervous system lymphomas-Assessment and treatment and prevention of central nervous system relapse
Paola Ghione, Katharine L Lewis, Sabela Bobillo, et al.
Cancers
|
February 13, 2026
The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System
Julia Wendler, Benjamin Kasenda, Eliza M Lauer, et al.
BMC Cancer
|
April 22, 2016
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix)
Elisabeth Schorb, Juergen Finke, Andrés J M Ferreri, et al.
BMC Cancer
|
September 10, 2022
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma
Julia Wendler, Christopher P Fox, Elke Valk, et al.
Cancers
|
December 11, 2025
Role of Geriatric Assessment Scores as Predictors of Intensive Therapy Feasibility and Survival in Elderly Patients with Primary CNS Lymphoma
Lisa K Isbell, Annika Vreden, Gabriele Ihorst, et al.
Page
of 5